[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CytomX Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100551646",false,"NCT06462794","First In Human Study of CX-801 in Advanced Solid Tumors","An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors","Inclusion Criteria:\n\n* Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Measurable disease per RECIST v1.1\n* Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue\n* Adequate organ function\n* Additional inclusion criteria may apply\n\nExclusion Criteria:\n\n* Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated\n* Known active central nervous system (CNS) involvement by malignancy\n* Prior PD-1\u002F PD-(L)1 inhibitor treatment discontinued due to grade 3 or higher immune related adverse event\n* Systemic anticancer treatment within 4 weeks or 5 half lives prior to first dose of study treatment\n* Investigational drug or device within 4 weeks prior to first dose of study treatment\n* Radiation within 2 weeks prior to first dose of study treatment\n* Serious concurrent illness\n* Pregnant or breast feeding\n* Additional exclusion criteria may apply","ALL","18 Years",{"count":18,"type":19},121,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.",[25],"Solid Tumor, Adult","RECRUITING","2026-06-25",{"date":29,"type":30},"2026-06-29","ACTUAL",{"date":32,"type":30},"2024-08-28",{"date":34,"type":19},"2029-06-30",{"name":36,"class":37},"CytomX Therapeutics","INDUSTRY",4,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":47,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":57},"100536504","NCT06265688","First In Human Study of CX-2051 in Advanced Solid Tumors","An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Measurable disease per RECIST v1.1\n* Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue\n* Additional inclusion criteria may apply\n\nExclusion Criteria:\n\n* Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated\n* Known active central nervous system (CNS) involvement by malignancy\n* Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1\n* Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload\n* Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1\n* Elevated baseline laboratory values\n* Serious concurrent illness\n* Pregnant or breast feeding\n* Additional exclusion criteria may apply",{"count":46,"type":19},160,[22],"The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.",[25],"2026-06-23",{"date":27,"type":30},{"date":53,"type":30},"2024-04-02",{"date":55,"type":19},"2029-03-31",{"name":36,"class":37},7,""]